Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Chronic Lymphoid Leukemia Clinical Trial

Official title:

Preemptive Therapy With Venetoclax for High Risk Chronic Lymphoid Leukemia Stage A Patients, a Phase II Trial of the FILO

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03766763
• Other study ID #: PREVENE FILOCLL10
• Status: Recruiting
• Phase: Phase 2
• Start date: May 22, 2019
• Est. completion date: February 1, 2028

Study information

• Verified date: July 2022
• Source: French Innovative Leukemia Organisation
• Contact: Delphine NOLLET
• Phone: (33) 2 18 37 06 09
• Email: d.nollet[@]chu-tours.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open label, single arm, multicenter phase II trial.

Description:

Preemptive therapy with Venetoclax for high risk stage A Chronic Lymphoid Leukemia patients, a phase II trial of the FILO group. PREVENE (PREemptive VENEtoclax) trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 82
• Est. completion date: February 1, 2028
• Est. primary completion date: January 22, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Established diagnosis of Chronic Lymphoid Leukemia by International Workshop Chronic Lymphoid Leukemia 2008 criteria with Matutes score Superior to 3, or Matutes score egal to 3 with CD200 positive and CD20 low
• High risk Binet stage A, patients presenting at least 2 from 3 risk factors:

Lymphocytosis Superior to 13 Giga per liter, CD38 positive, beta2 microglobulin Superior to 2.5 milligram per liter. Only patients with unmutated status will be treated and followed according to the trial.

• No prior chemotherapy, radiation or antibody treatment
• Age Superior to 18 years
• Life expectancy Superior to 6 months
• Performance status 0 to 2
• All parameters for risk stratification present
• Possibility of follow-up
• Adequate hepatic function per local laboratory reference range as follows: Aspartate transaminase and alanine transaminase Superior to 3.0 of upper limit of normal and Bilirubin inferior or egal to 1.5 of upper limit of normal (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
• Willingness to accept highly effective methods of contraception for the duration of therapy and 12 months thereafter
• Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin) or urine pregnancy test at Screening.
• Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study

Exclusion Criteria:

• Binet Stage A patients with progressive disease according to International Workshop Chronic Lymphoid Leukemia 2008 criteria
• Clinically apparent autoimmune cytopenia, in particular antiglobulin test positive hemolytic anemia (positive antiglobulin test without anemia is not an exclusion criteria)
• Active secondary malignancy or chemotherapy/radiotherapy for any neoplastic disease other than Chronic Lymphoid Leukemia prior to the study
• Medical condition requiring the long term (estimated to be more than one month) use of oral corticosteroids
• Patient refusal to perform the bone marrow biopsy for evaluation points
• Patients with active bacterial, viral or fungal infection
• Subject is known to be positive for Human Immunodeficiency Virus
• Evidence of other clinically significant uncontrolled conditions
• Treatment with any other investigational agent or participating in another trial within 30 days prior to entering this study
• A female patient who is pregnant or breast feeding
• Concurrent severe diseases which exclude the administration of therapy
• Richter's syndrome
• Treatment with any of the following within 7 days prior to the first dose of study drug: Steroid therapy for anti-neoplastic intent, moderate or strong cytochrome P450 3A inhibitors, moderate or strong cytochrome P450 3A inducers
• Administration or consumption of any of the following within 3 days prior to the first dose of study drug: grapefruit or grapefruit products, Seville oranges, star fruit.
• Prior and concomitant therapy
• Malabsorption syndrome or other condition that precludes enteral route of administration
• Received a live viral vaccination within 6 months prior to the first dose of study drug. A significant history of renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, or hepatic disease that, in the opinion of the investigator, would adversely affect the patient's participation in this study or interpretation of study outcomes
• Major surgery within 30 days prior to the first dose of study treatment
• History of prior other malignancy that could affect compliance with the protocol or interpretation of results
• Not affiliated to social security

Related Conditions & MeSH terms

• Chronic Lymphoid Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Intervention

Drug:
• Venetoclax
Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day. For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ). For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment).

Locations

Country	Name	City	State
France	Chu Amiens	Amiens
France	Chu Angers	Angers
France	Ch Annecy	Annecy
France	Ch Cote Basque	Bayonne
France	Hopitaljean Minjoz	Besançon
France	Ch Beziers	Béziers
France	CH BLOIS	Blois
France	Institut Bergonie	Bordeaux
France	CHU CAEN	Caen
France	Hôpital Privé Sévigné	Cesson-Sévigné
France	Chu Estaing	Clermont-Ferrand
France	Chu Creteil	Créteil
France	Chu Grenoble	Grenoble
France	Chd Vendee	La Roche-sur-Yon
France	Chd Le Mans	Le Mans
France	Hopital Huriez	Lille
France	Centre leon berard	Lyon
France	Institut Paoli Calmette	Marseille
France	Centre Hospitalier Regional Metz Thionville	Metz
France	Bordeaux Pessac	Pessac
France	Centre Hospitalier Lyon Sud	Pierre-Bénite
France	Centre Henri Becquerel - Service Hématologie Clinique	Rouen
France	Hôpital Bretonneau - Hématologie et Thérapie Cellulaire	Tours

Sponsors (1)

Lead Sponsor	Collaborator
French Innovative Leukemia Organisation

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete response rate	according to International Workshop Chronic Lymphoid Leukemia 2008 guidelines and with Minimal Residual Disease inferior to 0.01 percent (as determined by 8-color technique) in bone marrow at month 12.	12 months

External Links

•   French Innovative Leukemia Organization (FILO) internet site